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Abstract. Parkinsonism can be the presenting feature of frontotemporal dementia due to Progranulin (GRN) mutations or
develop over the course of the disease, mimicking idiopathic Parkinson’s disease or atypical parkinsonism. Here we report
on a patient carrying a novel GRN mutation who presented with asymmetric parkinsonism and developed cognitive decline
and language alterations two years later. Brain MRI showed mild asymmetric fronto-parietal atrophy. Single-photon emission
computed tomography with I123 ioflupane (DAT-Scan) demonstrated reduced tracer uptake in the left putamen. Larger studies
are needed to clarify whether presynaptic dopaminergic deficit is present in all GRN mutation carriers or only in those with
parkinsonism.
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INTRODUCTION
Mutations in the Progranulin gene (GRN) have been
associated with various clinical phenotypes, the most
frequent one being behavioral variant frontotemporal
dementia (bvFTD), that accounts for about half of the
cases [1, 2]. However, even patients with no behavioral
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or cognitive symptoms at onset and without a clearly
autosomal dominant family history can be carriers of
mutations in the GRN gene [3–5].
Parkinsonism can be observed in patients with GRN
mutations both at onset and over the course of the
disease, sometimes resembling Parkinson’s disease
(PD) or atypical parkinsonism including Lewy body
dementia (LBD), corticobasal degeneration (CBD),
progressive supranuclear palsy (PSP), and multiple
system atrophy (MSA) ([6–8]; see [2] for review).
Interestingly, previous clinical and neuropathological
studies suggested that parkinsonism may be more fre-
quent in FTD patients with GRN mutations than in
non-carriers [9, 10].
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Diagnosis of FTD caused by GRN mutations is based
on clinical suspicion, low GRN plasma levels [11–13],
and positive genetic testing; brain MRI can also pro-
vide important clues for an accurate diagnosis, showing
asymmetrical frontal, temporal, and inferior parietal
lobe atrophy in most cases [2].
CASE REPORT
A right-handed Italian man presented with asym-
metric rest tremor of the right hand at age 51. His
past medical history included blood hypertension and
diabetes mellitus, both treated with oral drugs. There
was no family history of any neurological or psychi-
atric disorders, and the patient had no children. He
denied previous assumption of neuroleptics or expo-
sure to toxic agents. Two years after the onset of
symptoms, the tremor became more severe, interfering
with everyday activities, and he started complain-
ing of poor concentration, difficulties in calculation,
and memory deficits. He came to our attention at
age 53. Neurological examination showed hypomimic
face, asymmetric jerky rest, postural non-re-emergent
and action tremor in the right hand as well as mild
bradykinesia on finger-tapping on the same side. He
walked with stooped posture and reduced arm-swings
on the right side; muscular tone was increased in the
right arm with cogwheel rigidity in the elbow (See
Supplementary Video). His language was poor, with
stuttering and frequent paraphasias. Eye movement
examination revealed slow initiation of saccades. Brain
MRI showed bilateral fronto-temporal atrophy, slightly
more prominent on the left side with periventricu-
lar subcortical hyperintensities on FLAIR sequences
(Fig. 1). Accordingly, a perfusion SPECT displayed
bilateral frontal hypoperfusion, more marked on the
left side, with homolateral parieto-temporal hypop-
erfusion. Slow theta waves were visible on the left
hemisphere on EEG. Cerebrospinal fluid biomarkers
Fig. 1. Brain MRI (FLAIR sequences) demonstrating bilateral frontal and temporal atrophy, more marked on the left hemisphere; a) axial
images; b) coronal images.
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Fig. 2. DAT-Scan demonstrating reduced tracer uptake in the left putamen.
(A42, total tau, P-181 tau) were all in normal range.
Formal neuropsychometry revealed a Mini-Mental
State Exam score of 24/30, and language impairment
with semantic deficits.
The presence of parkinsonism with cognitive
impairment and language alterations, although with-
out behavioral symptoms, raised the suspicion of FTD,
supported by frontal and temporal atrophy on brain
MRI. Given the relatively high prevalence of GRN
mutations in sporadic FTD cases as compared to
MAPT mutations, we first assessed plasmatic Progran-
ulin concentration, which resulted markedly decreased
(13 pg/ml, normal values >70 pg/ml). Subsequently,
GRN sequencing revealed a novel variant in exon
9 (G387fs25X). To determine whether this was a
pathogenic variant, the patient’s mRNA was extracted
from peripheral mononuclear blood cells and retro-
transcribed to c-DNA. Subsequent sequencing showed
a wild type profile, therefore confirming that the
mutation leads to a premature stop codon with hap-
loinsufficiency.
To further investigate the nature of parkinsonism, a
SPECT with I123 ioflupane (DAT-Scan) was performed
showing reduced tracer uptake in the left putamen,
consistent with the patient’s right-sided parkinsonism
(Fig. 2).
Six months later, the patient presented behavioral
changes with hypersexuality and verbal aggressive-
ness. Low doses of Quetiapine (25 mg/day) were
started with good control of behavioral symptoms.
Given the pre-synaptic nature of parkinsonism as
showed by DAT-Scan, low doses of Levodopa/ Benser-
azide (100 mg/day) were started, warning the patient
about the potential development of behavioral side-
effects. Total daily dose was slowly increased up to
600 mg/day with no benefit on rest tremor, bradyki-
nesia, rigidity, and other parkinsonian signs; no side
effects were observed.
The disease course has been progressive so far; on
follow up one year after the diagnosis (3 years after the
onset), the patient had developed overt dementia with
apathy, severe language deficits with echolalia, urinary
incontinence, and complete loss of independence in the
activities of daily living. Parkinsonism has remained
relatively stable over time.
METHODS
Cerebrospinal fluid (CSF) was obtained in
polypropylene tubes by lumbar puncture at the L4/L5
interspace, centrifuged at 4◦C, and stored at ≤−30◦C
until analysis. A42, total tau, and P-181 tau CSF
levels were determined with human specific ELISA
kits (Innogenetics). A42 and tau reference levels
were considered according to Sjo¨gren et al. [14].
Regarding P-tau, we considered as reference value
the concentration suggested by the manufacturer’s
protocol (<61 pg/ml).
Plasma progranulin levels were evaluated with spe-
cific ELISA kits (Adipogene, Korea).
High-molecular weight DNA was isolated from
whole blood using a Flexigene Kit (Qiagen, Hil-
dren, Gemany), as described by the manufacturer. The
amount of DNA for each sample was determined using
a NanoDrop ND-3300® Fluorospectrometer. DNA
samples were aliquoted and stored at−20◦C until use.
The entire open reading frame including the noncoding
exon 0 and exon-intron boundaries of exons 1–12 of
the GRN gene was sequenced in FTLD patients, using
specific primers, as previously described [15]. Patient’s
consent was obtained to perform genetic analysis.
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DISCUSSION
GRN mutations are responsible for a significant
number of sporadic and familial cases of FTD with
variable clinical presentations. These include, as in our
case, movement disorders mimicking PD or atypical
parkinsonism [8, 16–19]. The patient reported herein
first presented with asymmetric rest tremor, while mild
cognitive deficits became evident only two years later,
followed by behavioral changes. His initial symptoms
at age 51 (mild asymmetric parkinsonism) were possi-
bly consistent with PD, as no atypical additional signs
or symptoms were detected at onset or in the first
two years of the disease. However, formal neuropsy-
chometry at age 53 as well as detailed neurological
examination revealed language deficits and cognitive
decline more severe than expected in a patient with PD
complicated by PD dementia (PDD). In this context,
abnormal DAT-Scan could have led to either a diagno-
sis of PDD or atypical parkinsonism, such as CBD.
Little is known about the pathogenesis of move-
ment disorders in FTLD and large studies investigating
the nature of parkinsonism in FTLD patients with or
without GRN mutations are lacking. Neuropatholog-
ical studies by Josephs et al. [9] showed that GRN
positive patients display a more prominent degener-
ation of the substantia nigra and caudate nuclei as
compared to GRN-negative FTD cases. Accordingly,
we first provide evidence of pre-synaptic dopaminer-
gic deficit in a GRN mutation carrier. Whether this is a
mutation and/or phenotype-specific effect present only
in a subset of subjects with FTD and parkinsonism or
in specific GRN mutations is yet to be determined with
larger studies.
Parkinsonism in FTLD is generally poorly or
not responsive to Levodopa [11, 16], similarly to
most cases of atypical parkinsonism, although differ-
ent degrees of clinical improvement after Levodopa
administration have been reported [5, 13]. In our case,
extrapyramidal signs did not improve with Levodopa,
although we cannot exclude that quetiapine partially
reduced its effect being a dopamine-receptor blocking
agent.
Alterations of dopamine synthesis along the nigro-
striatal pathway due to degeneration of neurons of the
substantia nigra is reflected by abnormal DAT-tracer
uptake and has been demonstrated in various neurode-
generative disorders in which parkinsonism can be
part of the clinical picture at different stages. These
include SCA2, SCA 3, SCA6, and SCA17 [20–22],
Cerebrotendinous Xanthomatosis [23], and early-onset
dystonia-parkinsonism due to PLA2G6 mutations [24];
alterations of DAT-Scan have been shown in idio-
pathic REM sleep behavior disorder as well [25], and
in fragile X-associated tremor ataxia syndrome [26].
Recently, O’Dowd and colleagues described a patient
carrying a pathogenic C9Orf72 hexanucleotide expan-
sion presenting with a complex phenotype including
amyotrophic lateral sclerosis, FTD, and parkinsonism
who also showed abnormal DAT-Scan [27].
However, extensive studies investigating reduced
dopamine synthesis in FTLD have not been performed
yet. Here we show for the first time that a pre-synaptic
dopamine deficit is present in a patient with FTD due
to GRN mutations presenting with asymmetric parkin-
sonism, thus adding another possible differential to the
list of atypical parkinsonism with abnormal DAT-Scan
(MSA, PSP, CBD, LBD) and providing a rationale
for the treatment of movement disorders in FTD with
parkinsonism, despite no studies to assess the effective-
ness of Levodopa or dopamine-agonists in FTD with
parkinsonism are available and our case did not show
a significant improvement on LD treatment.
In conclusion, we describe a novel GRN mutation
leading to haploinsufficiency, presenting with atypi-
cal parkinsonism, language dysfunction, and a rapid
progression to full blown dementia. Furthermore, we
describe for the first time alterations of DAT-Scan in a
case of FTD due to GRN mutations. This description
enlarges the spectrum of known GRN mutations and
related clinical phenotypes.
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